Drug Trial Radar · NCT07681596
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
101
Planned (sponsor's estimate)
Start
Jul 27, 2026
Primary completion
Mar 6, 2031
Study completion Mar 6, 2031
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jul 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the treatment of adult participants with RRMM.
Conditions
- Relapsed or Refractory Multiple Myeloma
Interventions
AZD4045Biological
Allogeneic Chimeric Antigen Receptor T cell (CAR-T) Therapy Targeting B Cell Maturation Antigen (BCMA)
DaratumumabDrug
Anti-CD38 monoclonal antibody
AldesleukinDrug
Recombinant human IL-2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AEs) and serious AEs (SAEs)Time frame: Through study completion, an average of 2 years
- Dose-limiting toxicities (DLT)Time frame: 28 days
Locations
12 sites in 2 countries. Site status is shown where the registry gives one.
Research Site
Duarte, California · Recruiting
Research Site
Denver, Colorado · Not yet recruiting
Research Site
Tampa, Florida · Not yet recruiting
Research Site
Atlanta, Georgia · Not yet recruiting
Research Site
St Louis, Missouri · Not yet recruiting
Research Site
Hackensack, New Jersey · Not yet recruiting
Research Site
Cleveland, Ohio · Withdrawn
Research Site
Nashville, Tennessee · Not yet recruiting
Research Site
Houston, Texas · Recruiting
Research Site
Milwaukee, Wisconsin · Withdrawn
Research Site
Camperdown, Australia · Not yet recruiting
Research Site
East Melbourne, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.